Takeda appoints Annapurna Das as the General Manager, India Operations
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Investing in Malaysia's largest clinic operator to expand the healthcare business
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
Subscribe To Our Newsletter & Stay Updated